Scholar Rock Holding Corp. (SRRK) NASDAQ
$13.95 0.25 (1.82%)
Market Cap: $1.09B
As of 04/18/24 04:00 PM EDT. Market closed.
Scholar Rock Holding Corp. (SRRK)
NASDAQ
$13.95
0.25 (1.82%)
Market Cap: $1.09B
As of 04/18/24 04:00 PM EDT. Market closed.
scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental ... read more
scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Myles Edward H | COO & CFO | Feb 16, 2024 | Sale | $15.74 | 4,744 | 74,686 | 210,976 | Feb 21, 2024, 06:13 PM |
Parlavecchio Caryn | CHRO | Feb 16, 2024 | Sale | $15.74 | 3,751 | 59,053 | 157,744 | Feb 20, 2024, 04:52 PM |
Ho Junlin | GENERAL COUNSEL | Feb 16, 2024 | Sale | $15.74 | 3,489 | 54,928 | 208,771 | Feb 20, 2024, 04:48 PM |
Backstrom Jay T. | CHIEF EXECUTIVE OFFICER | Feb 16, 2024 | Sale | $15.74 | 11,614 | 182,842 | 352,671 | Feb 20, 2024, 04:46 PM |
Qatanani Mo | SVP AND HEAD OF RESEARCH | Jan 16, 2024 | Sale | $15.93 | 2,002 | 31,889 | 78,816 | Jan 18, 2024, 04:11 PM |
Parlavecchio Caryn | CHRO | Jan 16, 2024 | Sale | $15.93 | 2,849 | 45,381 | 114,350 | Jan 18, 2024, 04:08 PM |
Myles Edward H | COO & CFO | Jan 16, 2024 | Sale | $15.93 | 6,634 | 105,670 | 162,150 | Jan 18, 2024, 04:07 PM |
Ho Junlin | GENERAL COUNSEL | Jan 16, 2024 | Sale | $15.93 | 4,186 | 66,677 | 154,405 | Jan 18, 2024, 04:05 PM |
Myles Edward H | COO & CFO | Dec 29, 2023 | Option Exercise | $4.86 | 12,459 | 60,551 | 181,243 | Dec 29, 2023, 07:13 PM |
Myles Edward H | COO & CFO | Dec 29, 2023 | Sale | $18.83 | 12,459 | 234,633 | 169,084 | Dec 29, 2023, 07:13 PM |
Qatanani Mo | SVP AND HEAD OF RESEARCH | Dec 14, 2023 | Option Exercise | $10.00 | 8,437 | 84,370 | 105,480 | Dec 15, 2023, 04:13 PM |
Qatanani Mo | SVP AND HEAD OF RESEARCH | Dec 14, 2023 | Sale | $18.18 | 24,662 | 448,444 | 80,818 | Dec 15, 2023, 04:13 PM |
Myles Edward H | COO & CFO | Dec 07, 2023 | Option Exercise | $4.86 | 24,914 | 121,082 | 193,698 | Dec 08, 2023, 04:12 PM |
Myles Edward H | COO & CFO | Dec 07, 2023 | Sale | $17.53 | 24,914 | 436,820 | 168,784 | Dec 08, 2023, 04:12 PM |
Myles Edward H | COO & CFO | Nov 02, 2023 | Sale | $12.51 | 35,007 | 438,039 | 168,784 | Nov 03, 2023, 06:11 PM |
AKKARAJU SRINIVAS | Director | Oct 16, 2023 | Buy | $6.85 | 2,189,781 | 15,000,000 | 6,788,609 | Oct 18, 2023, 05:46 PM |
Samsara BioCapital GP, LLC | 10% Owner | Oct 16, 2023 | Buy | $6.85 | 2,189,781 | 15,000,000 | 6,788,609 | Oct 18, 2023, 05:44 PM |
Invus Public Equities, L.P. | 10% Owner | Oct 12, 2023 | Buy | $6.86 | 2,199,931 | 15,086,735 | 11,259,438 | Oct 16, 2023, 05:46 PM |
Qatanani Mo | SVP AND HEAD OF RESEARCH | Sep 18, 2023 | Sale | $6.34 | 1,945 | 12,331 | 97,043 | Sep 20, 2023, 07:28 PM |
Parlavecchio Caryn | CHRO | Aug 16, 2023 | Sale | $6.83 | 1,353 | 9,241 | 117,199 | Aug 18, 2023, 04:05 PM |
Parlavecchio Caryn | CHRO | Jun 21, 2023 | Option Exercise | $8.75 | 4,038 | 35,332 | 118,552 | Jun 22, 2023, 06:35 PM |
Myles Edward H | COO & CFO | Jun 21, 2023 | Option Exercise | $8.75 | 7,138 | 62,456 | 203,791 | Jun 22, 2023, 06:33 PM |
Ho Junlin | GENERAL COUNSEL | Jun 21, 2023 | Option Exercise | $8.75 | 4,346 | 38,027 | 158,591 | Jun 22, 2023, 06:31 PM |
Invus Public Equities, L.P. | 10% Owner | Apr 28, 2023 | Buy | $6.43 | 31,557 | 202,845 | 9,059,507 | May 02, 2023, 09:00 PM |
Myles Edward H | COO & CFO | Jan 17, 2023 | Option Exercise | $11.29 | 7,043 | 79,503 | 147,179 | Jan 19, 2023, 06:21 PM |
Parlavecchio Caryn | CHRO | Jan 17, 2023 | Option Exercise | $11.28 | 2,934 | 33,096 | 75,715 | Jan 19, 2023, 06:18 PM |
Ho Junlin | GENERAL COUNSEL | Jan 17, 2023 | Option Exercise | $11.29 | 4,529 | 51,125 | 116,062 | Jan 19, 2023, 06:16 PM |
Invus Public Equities, L.P. | 10% Owner | Jan 09, 2023 | Sale | $9.48 | 1,094 | 10,373 | 9,027,950 | Jan 11, 2023, 08:30 PM |
Invus Public Equities, L.P. | 10% Owner | Jan 05, 2023 | Buy | $9.33 | 48,774 | 455,091 | 9,029,044 | Jan 09, 2023, 05:22 PM |
Invus Public Equities, L.P. | 10% Owner | Oct 25, 2022 | Buy | $8.04 | 130,265 | 1,047,383 | 8,980,270 | Oct 27, 2022, 04:36 PM |
Invus Public Equities, L.P. | 10% Owner | Oct 04, 2022 | Buy | $7.89 | 66,000 | 520,760 | 8,850,005 | Oct 07, 2022, 04:30 PM |
Invus Public Equities, L.P. | 10% Owner | Oct 03, 2022 | Buy | $7.03 | 33,971 | 238,789 | 8,784,005 | Oct 07, 2022, 04:30 PM |
Parlavecchio Caryn | CHRO | Aug 16, 2022 | Option Exercise | $11.34 | 1,401 | 15,887 | 78,649 | Aug 17, 2022, 05:00 PM |
Nashat Amir | Director | Jun 22, 2022 | Buy | $4.90 | 1,197,992 | 5,870,161 | 3,540,530 | Jun 24, 2022, 04:27 PM |
Ho Junlin | General Counsel | Jan 18, 2022 | Option Exercise | $19.46 | 1,042 | 20,280 | 37,591 | Jan 19, 2022, 07:02 PM |
Myles Edward H | Chief Financial Officer | Jan 18, 2022 | Option Exercise | $19.46 | 2,178 | 42,390 | 21,972 | Jan 19, 2022, 07:01 PM |
CHYUNG YUNG H. | Chief Medical Officer | Jan 18, 2022 | Option Exercise | $19.46 | 1,421 | 27,657 | 220,996 | Jan 19, 2022, 07:01 PM |
Carven Gregory John | Chief Scientific Officer | Jan 18, 2022 | Option Exercise | $19.46 | 1,137 | 22,129 | 47,708 | Jan 19, 2022, 07:00 PM |
Myles Edward H | Chief Financial Officer | Nov 11, 2021 | Sale | $35.20 | 23,574 | 829,857 | 24,150 | Nov 15, 2021, 09:28 PM |
Myles Edward H | Chief Financial Officer | Nov 15, 2021 | Sale | $35.05 | 4,879 | 171,006 | 24,150 | Nov 15, 2021, 09:28 PM |
Myles Edward H | Chief Financial Officer | Nov 12, 2021 | Sale | $35.12 | 49,848 | 1,750,438 | 24,150 | Nov 15, 2021, 09:28 PM |
FLIER JEFFREY S. | Director | Oct 01, 2021 | Sale | $30.89 | 6,000 | 185,329 | 22,272 | Oct 05, 2021, 08:15 AM |
FLIER JEFFREY S. | Director | Sep 20, 2021 | Sale | $34.09 | 500 | 17,045 | 9,013 | Sep 21, 2021, 04:46 PM |
FLIER JEFFREY S. | Director | Jul 26, 2021 | Sale | $31.66 | 6,000 | 189,954 | 31,309 | Jul 28, 2021, 04:17 PM |
Gilman Michael | Director | Mar 15, 2021 | Sale | $65.59 | 4,696 | 307,998 | 37,459 | Mar 17, 2021, 05:03 PM |
Gilman Michael | Director | Feb 08, 2021 | Sale | $65.06 | 1,804 | 117,361 | 42,155 | Feb 11, 2021, 07:14 AM |
Carven Gregory John | Head of Research | Jan 27, 2021 | Sale | $56.57 | 19,100 | 1,080,402 | 46,434 | Jan 28, 2021, 09:53 PM |
Carven Gregory John | Head of Research | Jan 26, 2021 | Sale | $60.91 | 3,607 | 219,687 | 52,898 | Jan 28, 2021, 09:53 PM |
Gilman Michael | Director | Jan 26, 2021 | Option Exercise | $5.77 | 3,501 | 20,201 | 47,460 | Jan 28, 2021, 05:48 PM |
Gilman Michael | Director | Jan 26, 2021 | Sale | $59.26 | 3,501 | 207,469 | 46,977 | Jan 28, 2021, 05:48 PM |
Carven Gregory John | Head of Research | Jan 26, 2021 | Option Exercise | $8.86 | 30,900 | 273,822 | 76,115 | Jan 28, 2021, 05:47 PM |
Carven Gregory John | Head of Research | Jan 27, 2021 | Option Exercise | $15.11 | 6,619 | 100,013 | 82,734 | Jan 28, 2021, 05:47 PM |
Carven Gregory John | Head of Research | Jan 27, 2021 | Sale | $56.57 | 19,100 | 1,080,402 | 40,560 | Jan 28, 2021, 05:47 PM |
Carven Gregory John | Head of Research | Jan 26, 2021 | Sale | $59.41 | 36,774 | 2,184,820 | 78,058 | Jan 28, 2021, 05:47 PM |
Polaris Venture Management Co. VI, L.L.C. | 10% Owner | May 29, 2018 | Buy | $14.00 | 7,887 | 110,418 | 156,395 | May 31, 2018, 09:43 PM |
Polaris Venture Management Co. VI, L.L.C. | 10% Owner | May 29, 2018 | Buy | $14.00 | 134,970 | 1,889,580 | 2,676,311 | May 31, 2018, 09:43 PM |
Nashat Amir | Director | May 29, 2018 | Buy | $14.00 | 7,887 | 110,418 | 156,395 | May 31, 2018, 09:42 PM |
Nashat Amir | Director | May 29, 2018 | Buy | $14.00 | 134,970 | 1,889,580 | 2,676,311 | May 31, 2018, 09:42 PM |
Artal International S.C.A. | 10% Owner | May 29, 2018 | Buy | $14.00 | 450,000 | 6,300,000 | 450,000 | May 31, 2018, 09:41 PM |
SPRINGER TIMOTHY A | Director | May 29, 2018 | Buy | $14.00 | 71,428 | 999,992 | 3,273,519 | May 31, 2018, 09:41 PM |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
BLACKROCK INC. | 4,962,597 | 0.00238% | 42.58% | Other |
ORBIMED ADVISORS LLC | 4,245,000 | 1.59% | 108.72% | Other |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,300,000 | 0.05% | New | Other |
GEODE CAPITAL MANAGEMENT, LLC | 1,141,547 | 0.00225% | 33.82% | Other |
FISHER ASSET MANAGEMENT, LLC | 113,164 | 0.00112% | -19.77% | Other |
D. E. SHAW & CO., INC. | 95,291 | 0.00157% | 38.46% | Other |
UBS OCONNOR LLC | 85,129 | 0.12% | -59.95% | Value |
TUDOR INVESTMENT CORP ET AL | 25,292 | 0.00383% | New | Event Driven, Other |
BLACKSTONE INC. | 18,343 | 0.00155% | New | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View